FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer

被引:42
|
作者
Akita, H. [1 ]
Takahashi, H. [1 ]
Ohigashi, H. [2 ]
Tomokuni, A. [1 ]
Kobayashi, S. [1 ]
Sugimura, K. [1 ]
Miyoshi, N. [1 ]
Moon, J. -H. [1 ]
Yasui, M. [1 ]
Omori, T. [1 ]
Miyata, H. [1 ]
Ohue, M. [1 ]
Fujiwara, Y. [1 ]
Yano, M. [1 ]
Ishikawa, O. [1 ]
Sakon, M. [1 ]
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis OMCC, Dept Surg, Osaka, Japan
[2] Saiseikai Senri Hosp, Dept Surg, Suita, Osaka, Japan
来源
EJSO | 2017年 / 43卷 / 06期
关键词
Pancreatic cancer; Neoadjuvant; Chemoradiotherapy; FDG-PET; POSITRON-EMISSION-TOMOGRAPHY; GEMCITABINE-BASED CHEMORADIATION; PATHOLOGICAL RESPONSE; ADENOCARCINOMA; SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY; RECURRENCE; PACLITAXEL; MANAGEMENT;
D O I
10.1016/j.ejso.2017.03.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The efficacy of neoadjuvant chemoradiotherapy (NACRT) for resectable and borderline resectable pancreatic cancer is important for predicting outcomes after radical surgery, but few clinical indicators predict outcome before resection. This study examined the utility of FDG-PET in predicting the efficacy of NACRT and outcome after radical surgery. Methods: Eighty-three pancreatic cancer patients who underwent FDG-PET before and after NACRT and had positive standard uptake values (SUVs) before NACRT were enrolled in this study. Peri-operative clinical factors, including FDG-PET findings, were examined to predict the efficacy of NACRT and outcome after surgery. Results: Evans grade I, IIA, [03, III, and IV was determined in 11, 31, 27, 11, and 3 patients, respectively. The maximum SUVs after NACRT (post SUV-max) and tumor size were significantly decreased compared to pretreatment values (p < 0.001 and p = 0.007, respectively). The post SUV-max and regression index were significantly related to grade III/IV (p = 0.04 and p < 0.001, respectively), but only the regression index predicted NACRT efficacy (p = 0.002). The AUC of the regression index for the detection of grade III/IV was 0.822, and 13 of 14 grade lII/IV patients were picked up using 50% as the threshold (p < 0.001). Patients with a regression index >50% had a significantly better prognosis after radical resection than patients with <50% (p = 0.032). Regression index as well as pathological lymph node status and resectability status were independent prognostic factors in multivariate analysis (exp 2.086, p = 0.043). Conclusion: The regression index is potentially a good indicator of the efficacy of NACRT and outcome after radical resection for pancreatic cancer. (C) 2017 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1061 / 1067
页数:7
相关论文
共 50 条
  • [41] Efficacy of Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer With Portal Vein or Arterial Involvement
    Nagakawa, Y.
    Takishita, C.
    Hijikata, Y.
    Murakami, Y.
    Yamaue, H.
    Satoi, S.
    Unno, M.
    Isaji, S.
    Endo, I.
    Sho, M.
    Fujii, T.
    Takaori, K.
    Suzuki, S.
    Ohta, T.
    Nagakawa, T.
    Tsuchida, T.
    PANCREAS, 2019, 48 (10) : 1495 - 1495
  • [42] Pathologic response, toxicity and outcomes for three pre-operative chemoradiation regimens for resectable, locally advanced stomach cancer
    Gopal, R
    Janjan, NA
    Crane, CH
    Ballo, MT
    Mansfield, PF
    Ajani, JA
    CANCER JOURNAL, 2001, 7 (06): : 529 - 529
  • [43] The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review
    Laura Evangelista
    Pietro Zucchetta
    Lucia Moletta
    Simone Serafini
    Gianluca Cassarino
    Nicola Pegoraro
    Francesca Bergamo
    Cosimo Sperti
    Diego Cecchin
    Annals of Nuclear Medicine, 2021, 35 : 767 - 776
  • [44] The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review
    Evangelista, Laura
    Zucchetta, Pietro
    Moletta, Lucia
    Serafini, Simone
    Cassarino, Gianluca
    Pegoraro, Nicola
    Bergamo, Francesca
    Sperti, Cosimo
    Cecchin, Diego
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (07) : 767 - 776
  • [45] Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer
    Im, Hyung-Jun
    Oo, Suthet
    Jung, Woohyun
    Jang, Jin-Young
    Kim, Sun-Whe
    Cheon, Gi Jeong
    Kang, Keon Wook
    Chung, June-Key
    Kim, E. Edmund
    Lee, Dong Soo
    MEDICINE, 2016, 95 (19)
  • [46] Prognostic significance of pre-operative FDG-PET in colorectal cancer patients with hepatic metastasis
    Lee, Hyo Sang
    Lee, Won Woo
    Kim, Duck-Woo
    Kang, Sung-Bum
    Kim, Sang Eun
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [47] Efficacy of Chemoradiation in Locally Advanced (Borderline Resectable and Unresectable) Pancreatic Cancer Remaining Unresectable After Neoadjuvant Chemotherapy
    Weir, J. S.
    McLean, K.
    Henson, C.
    Morton, J.
    Pant, S.
    George, S.
    Aljumaily, R.
    Postier, R.
    Herman, T. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E198 - E198
  • [48] Preoperative SUVmax Measured in FDG-PET Predicts Disease Free Survival After Resection of Resectable Pancreatic Ductal Adenocarcinoma
    Lee, Jae Woo
    Ryu, Ji Kon
    Son, Jun Hyuk
    Jang, Dong Kee
    Lee, Sang Hyub
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2016, 150 (04) : S612 - S612
  • [49] Does the Addition of FDG-PET to the Standard Pre-operative Work up of Pancreatic Cancer Change Management - a Prospective Study
    Burge, M.
    Houston, K. E.
    Francesconi, A.
    O'Rourke, N.
    Lee, J.
    Macfarlane, D.
    Wyld, D.
    Hopkins, G.
    Finch, R.
    Nathanson, L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S449 - S449
  • [50] Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer
    Goethals, L
    Haustermans, K
    Perneel, C
    Bussels, B
    D'Hoore, A
    Geboes, K
    Ectors, N
    Van Cutsem, E
    Van den Bogaert, W
    Penninckx, F
    EJSO, 2005, 31 (09): : 969 - 976